Zevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Misses Expectations By $0.28 EPS

Zevra Therapeutics (NASDAQ:ZVRA) announced its quarterly earnings results on Tuesday. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28), Zacks reports. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA traded up $0.07 during midday trading on Tuesday, hitting $8.07. The stock had a trading volume of 680,671 shares, compared to its average volume of 396,788. The company’s 50-day moving average price is $7.96 and its 200-day moving average price is $8.14. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $430.74 million, a P/E ratio of -4.10 and a beta of 1.98.

Wall Street Analyst Weigh In

ZVRA has been the topic of several research reports. Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group lowered their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Guggenheim set a $21.00 price target on shares of Zevra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 4th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $21.71.

Insider Buying and Selling

In other news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the transaction, the executive vice president now owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 85,773 shares of company stock worth $674,176. Corporate insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.